PHASE-1 provides National Cancer Institute with key toxicogenomic service
PHASE-1 Molecular Toxicology today announced it is providing key toxicogenomics services for the National Cancer Institute (NCI). This service will provide insight into cancer treatments and the toxicity produced by these agents in comparison to the mechanism of antitumor action.
(PRWEB) May 11, 2003
For Immediate Release
Contact: Jim Faulkner - Director Business Development
PHASE-1 Molecular Toxicology, Inc.
2904 Rodeo Park Drive East, Santa Fe, New Mexico 87505
Jfaulkner@phase1tox. com; telephone: (505) 424-2122; Fax: (505)471-8205.
PHASE-1 provides National Cancer Institute with key toxicogenomic service
Santa Fe, NM (PRWEB) May 9, 2003 – PHASE-1 Molecular Toxicology today announced it is providing key toxicogenomics services for the National Cancer Institute (NCI). This service will provide insight into cancer treatments and the toxicity produced by these agents in comparison to the mechanism of antitumor action.
Toxicogenomics represents an emerging field of toxicology that is rapidly gaining in both credibility and importance. The field is the product of biotechnology and informational technology, making use of the explosive growth of human and animal genome data and advances in computer software for data archiving and mining.
“We are very pleased to have the National Cancer Institute as our client. Toxicogenomics is gaining recognition as a tool to define adverse drug toxicity. The service we provide to NCI will aid the selection of potent anticancer drugs with minimal side effects and help define the mechanism responsible for toxicity.” said Albert Li, PhD, President and CEO of PHASE-1.
PHASE-1 will be receiving animal tissues from multiple contract laboratories performing preclinical safety studies for the National Cancer Institute. The animal tissues will be evaluated for treatment related gene expression effects in the laboratories of PHASE-1.
“The reason we went with PHASE-1 is that they have toxchips for the relevant species in which we perform our toxicity studies” said Joseph E. Tomaszewski, Ph. D., Chief, Toxicology and Pharmacology Branch.
About PHASE-1
PHASE-1 Molecular Toxicology, Inc. (http://www. phase1tox. com (http://www. phase1tox. com)) was founded in 1995 as a Toxicogenomics company – the first commercial Toxicogenomics Corporation in world history. Currently, PHASE-1 remains the only company totally dedicated to Toxicogenomics. PHASE-1’s core competencies are centered on animal gene expression (Animal Toxicogenomics) and human gene expression (Human Toxicogenomics) products and services. Tullis Dickerson, a nationally recognized life science venture capital fund, is a major investor in the company.
About NCI
The National Cancer Institute (NCI) is a component of the National Institutes of Health (NIH), one of eight agencies that compose the Public Health Service (PHS) in the Department of Health and Human Services (DHHS). The NCI, established under the National Cancer Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. The Developmental Therapeutics Program in NCI has been involved in the development of new cancer treatments since 1955.
# # #
